Viridian Therapeutics Inc
VRDN17.290USD
-0.120-0.69%
交易中 （美東）報價延遲15分鐘
1.41B總市值
虧損本益比TTM
關於 Viridian Therapeutics Inc 公司
Viridian Therapeutics, Inc. 是一家生物製藥公司，專注於爲患有嚴重和罕見疾病的患者設計和開發潛在藥物。該公司正在臨牀上推進多種治療甲狀腺眼病 (TED) 患者的候選藥物。該公司正在進行兩項全球 3 期臨牀試驗 (THRIVE 和 THRIVE-2)，以評估 VRDN-001 對活動性和慢性 TED 患者的安全性和有效性。該公司專注於推進 VRDN-001 作爲潛在靜脈療法，隨後推進 VRDN-003 作爲治療 TED 的潛在皮下療法。其高級項目 VRDN-001 是一種針對 IGF-1R 的差異化人源化單克隆抗體，通過靜脈注射用於治療 TED。除了 TED 產品組合外，該公司還在推進一種新型新生兒 Fc 受體 (FcRn) 抑制劑產品組合，包括 VRDN-006 和 VRDN-008，這些抑制劑有可能在多種自身免疫性疾病中得到開發。
公司簡介
公司代碼VRDN
公司名稱Viridian Therapeutics Inc
上市日期Jun 18, 2014
CEOMr. Stephen (Steve) Mahoney
員工數量143
證券類型Ordinary Share
年結日Jun 18
公司地址221 Crescent Street
城市WALTHAM
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02453
電話16172724600
網址https://www.viridiantherapeutics.com/
公司代碼VRDN
上市日期Jun 18, 2014
CEOMr. Stephen (Steve) Mahoney
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+40.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+161.40%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Mr. Jeff Ajer
Mr. Jeff Ajer
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen (Steve) Mahoney
Mr. Stephen (Steve) Mahoney
President, Chief Executive Officer, Director (Principal Executive Officer)
President, Chief Executive Officer, Director (Principal Executive Officer)
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+40.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+161.40%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Mr. Jeff Ajer
Mr. Jeff Ajer
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
72.00K
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.78%
Deep Track Capital LP
6.53%
BlackRock Institutional Trust Company, N.A.
6.19%
Kynam Capital Management LP
5.71%
The Vanguard Group, Inc.
5.52%
Other
63.26%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.78%
Deep Track Capital LP
6.53%
BlackRock Institutional Trust Company, N.A.
6.19%
Kynam Capital Management LP
5.71%
The Vanguard Group, Inc.
5.52%
Other
63.26%
股東類型
持股股東
佔比
Hedge Fund
42.15%
Investment Advisor
36.83%
Investment Advisor/Hedge Fund
21.62%
Venture Capital
9.55%
Research Firm
2.42%
Private Equity
0.80%
Pension Fund
0.73%
Bank and Trust
0.51%
Corporation
0.11%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
366
94.59M
114.88%
-12.41M
2025Q1
387
93.96M
114.21%
-15.28M
2024Q4
381
93.18M
114.36%
-9.55M
2024Q3
354
88.84M
112.43%
+6.26M
2024Q2
331
71.47M
112.09%
-12.60M
2024Q1
329
71.87M
114.62%
-2.66M
2023Q4
309
61.41M
117.06%
+4.73M
2023Q3
286
52.92M
124.61%
-2.63M
2023Q2
276
50.12M
119.65%
-257.35K
2023Q1
259
46.00M
110.76%
-2.29M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
10.52M
12.78%
+350.50K
+3.45%
Mar 31, 2025
Deep Track Capital LP
5.38M
6.53%
+857.71K
+18.96%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.10M
6.19%
-74.84K
-1.45%
Mar 31, 2025
Kynam Capital Management LP
4.70M
5.71%
+1.37M
+41.30%
Mar 31, 2025
The Vanguard Group, Inc.
4.55M
5.52%
-31.95K
-0.70%
Mar 31, 2025
Commodore Capital LP
4.30M
5.22%
+700.00K
+19.44%
Apr 04, 2025
VR Adviser, LLC
3.88M
4.72%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
3.46M
4.2%
+14.10K
+0.41%
Jun 10, 2025
State Street Global Advisors (US)
2.87M
3.48%
-657.07K
-18.65%
Mar 31, 2025
Tang Capital Management, LLC
2.79M
3.39%
+300.00K
+12.03%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
ALPS Medical Breakthroughs ETF
0.77%
SPDR S&P Biotech ETF
0.27%
iShares Micro-Cap ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
Avantis US Small Cap Equity ETF
0.09%
Nuveen ESG Small-Cap ETF
0.08%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.06%
iShares Russell 2000 Growth ETF
0.05%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
ALPS Medical Breakthroughs ETF
佔比0.77%
SPDR S&P Biotech ETF
佔比0.27%
iShares Micro-Cap ETF
佔比0.22%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.15%
Avantis US Small Cap Equity ETF
佔比0.09%
Nuveen ESG Small-Cap ETF
佔比0.08%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.06%
iShares Russell 2000 Growth ETF
佔比0.05%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 12, 2020
Merger
15<1
Nov 12, 2020
Merger
15<1
Nov 12, 2020
Merger
15<1
Nov 12, 2020
Merger
15<1
公告日期
類型
比率
Nov 12, 2020
Merger
15<1
Nov 12, 2020
Merger
15<1
Nov 12, 2020
Merger
15<1
Nov 12, 2020
Merger
15<1
